Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research.

New York, United States, 10th Jul 2024—Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. The services tend to accelerate the discovery and optimization of molecule drugs with a strict quality control system. 

Small molecule drugs are characterized by their low molecular weight and simple chemical structures. These properties confer several advantages, including the ability to easily pass through cell membranes and the predictability of manufacturing, storage, and dosing. These drugs are usually designed to interact with specific targets (such as enzymes, receptors, and ion channels), and modify their activities to treat or prevent diseases. Developing effective small-molecule anti-cancer drugs is viewed as a promising approach to fight against cancer.

Small molecule drug development is the process of discovering and developing new drugs composed of relatively small organic molecules. The process typically involves several stages, including target identification and validation, hit identification and lead optimization, preclinical testing, and clinical trials. Throughout the entire process, Alfa Cytology holds a strict quality system with various services covering AI-based drug design, hit-to-lead, drug screening, and lead optimization. 

Furthermore, Alfa Cytology offers cancer model customization services to help study the complexity and heterogeneity of cancer. Various cancer models, from cell line models to genetically engineered mouse models and 3D organoid models, can be customized according to clients’ specific projects and targets. In addition, Alfa Cytology’s in vitro cancer modes are suitable for drug screening, mechanism study, and biomarker discovery, with enormous potential in promoting cancer research and therapy. Based on the advanced technologies and professional team, these models provide reliable data for each client through customized projects. What’s more, the streamlined workflows and optimized protocols ensure cost-efficient services without compromising on quality or reliability.

As the global crisis of cancer becomes increasingly severe, the emergence of new small molecule drugs and customized cancer models brings more hope. Alfa Cytology’s anti-cancer development solutions can help researchers deeply reflect on the diversity and precision of anti-cancer forms, providing novel choices for sustainable therapy.

About Alfa Cytology

Alfa Cytology is a biotech company known for its cancer preclinical CRO services. The team of Alfa Cytology brings together expertise in oncology, molecular biology, drug development, etc. With a deep understanding of the challenges and nuances of cancer research, Alfa Cytology provides innovative solutions and insights. 

Media Contact

Organization: Alfa Cytology

Contact Person: Thassia C.

Website: https://www.alfacytology.com/

Email: [email protected]

State: New York

Country: United States

Release Id: 10072414064

The post Alfa Cytology Announces Small Molecule Drug Development to Advance Preclinical Cancer Research appeared first on King NewsWire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

Australia, 10th Jul 2024 – Neuralia TMS is proud to announce the introduction of its cutting-edge Transcranial Magnetic Stimulation (TMS) therapy solutions in Como, designed to address depression and anxiety at their root neuraliatms.com.au. The company’s facility located at Unit 2A/125 Melville Parade, Marview House, Como WA 6152, is equipped to deliver this breakthrough treatment, which harnesses high-strength magnetic fields to stimulate neuroplasticity and promote increased neural connections in underactive brain regions.

TMS therapy, first developed in 1985 and approved by the FDA for the treatment of depression in 2008, has been recognised as a significant advancement in the treatment of mental health conditions. Since November 2021, it has been listed under Medicare for Treatment Resistant Depression, offering a new avenue of hope for individuals who have not responded to traditional treatments. This evidence-based therapy is supported by over 35 years of research, confirming its efficacy and safety.

Dr. Shanek Wick, spokesperson for Neuralia TMS, emphasises the importance of this development: “The introduction of TMS therapy at Neuralia TMS represents a significant milestone in mental health treatment in the Como area. TMS offers a non-invasive, drug-free option for individuals suffering from depression and anxiety, providing them with a new opportunity for recovery.”

TMS therapy works by stimulating neural activity in specific brain regions that are typically underactive in individuals with mental health conditions. For instance, decreased activity in the prefrontal cortex is often observed in those with depression and anxiety. This area of the brain is crucial for mood regulation, and by enhancing its activity, TMS helps alleviate symptoms associated with these conditions. PET scans of individuals with and without depression vividly illustrate the differences in prefrontal cortex activity, underscoring the potential of TMS to address these disparities.

The treatment process is designed to be quick and convenient, fitting seamlessly into daily routines without the need for recovery time or hospital admissions. This makes TMS an attractive option for those seeking effective treatment without the disruptions often associated with other therapies.

Dr. Wick further elaborates on the future outlook of TMS therapy: “The ongoing advancements in TMS technology and its expanding applications in treating various mental health conditions are promising. Neuralia TMS is committed to staying at the forefront of these developments, ensuring that the patients have access to the latest and most effective treatments available.”

In addition to treating depression and anxiety, TMS therapy shows potential for addressing other conditions such as chronic pain, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). The continued research and development in this field are expected to broaden the scope of TMS applications, offering new hope for individuals suffering from a range of neurological and psychological conditions.

Neuralia TMS’s new facility in Como is poised to become a centre of excellence for TMS therapy, staffed by a team of dedicated professionals committed to delivering the highest standards of care. The team at Neuralia TMS is well-versed in the latest TMS protocols and techniques, ensuring that each patient receives personalised and effective treatment.

For more information about Neuralia TMS and its new TMS Como therapy solutions, please contact the company at 08 6230 3996 or via email at [email protected]. 

Media Contact

Organization: Neuralia TMS Perth (Como)

Contact Person: Dr. Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: [email protected]

Contact Number: +61862303996

Address: Unit 2A/125 Melville Parade

Address 2: Marview House, Como WA 6152

Country: Australia

Release Id: 10072414065

The post Neuralia TMS Proudly Announces TMS Therapy Solutions in Como appeared first on King NewsWire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

Juan Sebastian Infante, a pioneering film director and creative visionary, has made significant contributions to Topaz Labs, a groundbreaking tech company specializing in artificial intelligence (AI). As the only Latino in the company, Infante brings a unique perspective and a wealth of experience to his role, making an indelible mark on the industry.

With over eight years of experience in network, television, and film projects, Infante’s career has been defined by his ability to transform innovative concepts into tangible creative endeavors. At Topaz Labs, he has directed high-impact commercials and content, driving the company’s video reach from zero to millions of views globally. His exceptional project management skills ensure that all initiatives align seamlessly with corporate objectives and overarching vision.

Among Infante’s notable projects at Topaz Labs are major releases such as Video AI, Photo AI, and Gigapixel. These products have revolutionized the way professionals and enthusiasts enhance and edit their visual content. Video AI, for example, uses advanced machine learning algorithms to upscale and enhance video footage, while Photo AI and Gigapixel provide unparalleled clarity and detail in photo editing.

Infante’s work at Topaz Labs is not just about creating visually stunning content; it’s about pushing the boundaries of what technology can achieve. His upcoming projects focus on enhancement imagery for mobile devices, promising to bring the power of Topaz Labs’ AI technology to a broader audience. These innovations will enable users to achieve professional-grade results with ease, further democratizing access to advanced imaging tools.

Infante’s contributions to Topaz Labs underscore his passion for blending film and technology, showcasing how he is at the forefront of this exciting intersection. His leadership and creativity continue to drive the company forward, ensuring that Topaz Labs remains a leader in the AI and tech space.

For more information about Juan Sebastian Infante and Topaz Labs, please visit topazlabs.com. and https://www.linkedin.com/in/infantedon

Contact details:

• Company name: Juan Sebastian Infante
• Website link: topazlabs.com
• Contact email: [email protected]
• Country: USA
• City: Dallas
• Contact person name: Juan Sebastian Infante (Don Infante)

TrustBet is set to transform the online gambling industry by harnessing blockchain technology and decentralized autonomous organizations (DAOs). Operating on the Solana blockchain, it tackles the prevalent issues of fraud and lack of transparency that have long plagued traditional gambling platforms. This innovative approach is set to capture the attention of both investors and gamblers alike.

A New Approach to Online Gambling

TrustBet leverages blockchain’s inherent transparency and security to offer a novel approach to online gambling. Blockchain technology has been recognized for its potential to democratize various industries. TrustBet builds on this by providing a trustless environment where smart contracts manage bet settlements, ensuring fairness and eliminating human interference. This model guarantees that all transactions are secure and transparent.

The Expanding Online Gambling Market

The online gambling market is booming, with projections estimating it will reach USD 153.57 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.7%, according to Grand View Research. Despite this growth, traditional gambling platforms are often marred by scandals involving non-payment of winnings. High-profile cases, such as Megan McCann’s dispute with Bet365, highlight the ongoing issues within the industry.

Challenges of Traditional Gambling Platforms

Traditional gambling sites frequently refuse to pay out winnings, citing various justifications. These legal battles usually favor corporations due to their vast resources. Additionally, these platforms have high operational costs, including exorbitant CEO salaries. TrustBet aims to address these issues by implementing a DAO-based structure, ensuring that the community governs the platform rather than a centralized authority.

TrustBet’s Operational Model

TrustBet’s operations are governed by a DAO, ensuring all decisions are made democratically by TBET token holders. This model promotes transparency and fairness, from profit allocation in the DAO’s staking facility to operational decisions which are subject to community votes. Smart contracts automate the process, providing a secure and immutable way to handle transactions and payouts, thereby eliminating the human element.

Exciting Presale and Tokenomics

TrustBet is currently in presale phase. Early investors benefit from a structured unlock schedule promoting price stability and rewards early participation, including airdrop multipliers. The presale requires a Solana functionality wallet, with Phantom Wallet being the recommended option. The platform’s financial structure emphasizes profit sharing, with 50% of the company’s profit allocated to TBET holders as monthly passive income paid in USDT.

Future Roadmap and Prospects

TrustBet’s extensive roadmap outlines its development and marketing plans. With significant new investments projected in the gamble-fi sector, TrustBet is well-positioned to capture a substantial market share by offering a decentralized and transparent gambling alternative.

Conclusion

TrustBet stands as a groundbreaking venture in the online gambling industry, addressing long-standing issues through blockchain technology and a DAO-based governance model. TrustBet ensures scalability, low costs, and a robust user experience. As the platform prepares for its main release, it offers a promising opportunity for early investors, significant passive income paid in USDT and a fair, transparent environment for gamblers.

For more information and to participate in the presale, visit TrustBet’s website. 

https://trustbetonchain.com/ 

Ottawa, ON – [9 july , 2024] – AGPLLP, a leading law firm in Ottawa, proudly announces its specialized services in handling drinking and driving cases. With a commitment to providing unparalleled legal expertise, AGPLLP has established itself as the go-to firm for individuals seeking robust defense and comprehensive legal support in Ottawa.

Comprehensive Legal Defense

AGPLLP understands the severe consequences that drinking and driving charges can have on an individual’s life. The firm’s experienced team of drinking and driving lawyers in Ottawa offers a meticulous and strategic approach to each case, ensuring that every client receives a thorough defense. The lawyers at AGPLLP are well-versed in the intricacies of the law and are dedicated to protecting the rights and freedoms of their clients.

Expertise and Experience

With years of experience in handling complex drinking and driving cases, AGPLLP’s legal team possesses a deep understanding of the legal system and the nuances of DUI (Driving Under the Influence) laws. The firm’s lawyers are renowned for their ability to navigate the legal landscape with precision and effectiveness, providing clients with the best possible outcomes.

Client-Centered Approach

At AGPLLP, clients are at the heart of everything they do. The firm’s drinking and driving lawyers in Ottawa prioritize clear communication, empathy, and personalized service. Understanding the stress and uncertainty that come with DUI charges, AGPLLP ensures that clients are fully informed and supported throughout the legal process. The firm’s client-centered approach has earned it a reputation for excellence and reliability in the Ottawa legal community.

Innovative Legal Strategies

AGPLLP’s legal team employs innovative strategies to challenge DUI charges, utilizing the latest legal precedents and forensic technology. The firm’s lawyers meticulously examine every detail of the case, from the legality of the traffic stop to the accuracy of breathalyzer tests. This comprehensive approach allows AGPLLP to identify and leverage any weaknesses in the prosecution’s case, significantly enhancing the chances of a favorable outcome for their clients.

Community Involvement and Education

Beyond providing exceptional legal services, AGPLLP is committed to raising awareness about the legal implications of drinking and driving. The firm actively participates in community outreach programs and educational initiatives aimed at preventing DUI offenses. By educating the public about the risks and consequences of drinking and driving, AGPLLP strives to contribute to a safer and more informed community.

Testimonials and Success Stories

AGPLLP’s success is reflected in the numerous positive testimonials and success stories from clients who have benefited from the firm’s expertise. One satisfied client remarked, “AGPLLP’s drinking and driving lawyers in Ottawa provided me with the support and defense I needed during a very challenging time. Their dedication and professionalism were evident throughout the process, and I am grateful for their help in securing a positive outcome.”

About AGPLLP

AGPLLP is a reputable law firm based in Ottawa, specializing in a wide range of legal services, including criminal defense, family law, personal injury, and more. With a team of highly skilled and experienced lawyers, AGPLLP is dedicated to delivering exceptional legal representation and achieving the best possible results for its clients.

Contact Information:

AGPLLP

Phone: +1 613-235-9779

Email: [email protected]

Website: https://www.agpllp.ca/

Address: 116 Lisgar Street, Suite 200 Ottawa, ON K2P 0C2

In a significant development for the gaming industry, Midas Labs has unveiled its latest venture, “Voyage to the West,” a platform designed for Community -building by Midas to revolutionize how independent game developers connect with global audiences. This new initiative aims to create a vibrant, inclusive ecosystem that not only empowers smaller gaming studios but also enhances player experiences through the integration of blockchain technology.

Midas Labs, known for its forward-thinking approach and commitment to innovation, has consistently focused on bridging gaps within the gaming community. With “Voyage to the West,” the company seeks to address the challenges smaller game developers face, such as limited resources for marketing and visibility, by providing a collaborative environment bolstered by comprehensive marketing support and a unified in-game currency, the Unifi token.

A Booming Market

The global online gaming market, valued at USD 175.8 billion in 2023, is projected to reach USD 268.8 billion by 2028, according to Newzoo. This exponential growth is driven by factors such as the rising popularity of mobile gaming and E-sports. Midas Labs aims to tap into this expanding market by offering indie developers the tools and exposure needed to thrive.

Empowering Voices of Independent Studios

Independent developers often struggle to compete with major studios that dominate the market. Many innovative games fail to gain traction due to a lack of awareness and marketing resources. “Voyage to the West” addresses this by creating a collaborative ecosystem where indie studios can connect, share resources, and leverage Midas Labs’ marketing prowess to reach a global audience.

“Voyage to the West” is more than just a platform; it is a community-building initiative inspired by the classic tale of Journey to the West. This thematic foundation encourages users to embark on epic quests, earn rewards, and participate in a dynamic, narrative-driven environment. By blending adventure with social elements, the platform aims to foster a passionate and engaged community.

Unifi Token: The Heart of the Ecosystem

Central to this ecosystem is the Unifi token (UNIFI), which serves as the primary currency within the Midas platform. Unifi can be earned through active participation in Voyage and used for in-game purchases, marketplace transactions, and staking for additional benefits. This multi-faceted utility not only incentivizes participation but also ensures a steady flow of rewards for users.

A Vision for the Future

Midas Labs envisions “Voyage to the West” as the first step in creating a multifaceted media empire. The platform’s phased development plan includes integrating more game studios, expanding its NFT marketplace, and introducing advertising opportunities within the ecosystem. By continually evolving and adapting to the needs of developers and players, Midas Labs aims to shape a vibrant, inclusive gaming landscape.

Conclusion

The launch of “Voyage to the West” marks a significant milestone in the gaming industry, offering a new lease on life for indie developers and a richer experience for gamers. Midas Labs’ innovative approach, leveraging blockchain technology and a strong community focus, sets a new standard for what a gaming platform can achieve. As the global gaming market continues to grow, “Voyage to the West” is poised to make a lasting impact, empowering developers and players alike.

For more info, please visit https://voyagewest.online/!

Company Name: Voyage To The West by Midas Labs

Contact Email: [email protected]

Contact Person: Alice Lindsey

Website link: https://voyagewest.online

SOURCE: Voyage To The West by Midas Labs

In a significant development aimed at transforming the Ethereum blockchain, Puffer Finance is thrilled to announce the impending launch of Puffer UniFi, a sophisticated based rollup solution designed to address key challenges in the Ethereum ecosystem. Puffer UniFi stands at the forefront of a series of innovations aimed at enhancing transaction efficiency, ensuring economic sustainability, and fostering widespread adoption of blockchain technology.

About Puffer UniFi

Puffer UniFi is an innovative based rollup that addresses critical issues such as the fragmentation of Layer 2 networks, the inefficient flow of value back to Ethereum’s Layer 1, and the lack of neutral transaction sequencing. By integrating seamlessly with Ethereum’s primary layer, Puffer UniFi significantly improves the security, simplicity, and user experience of blockchain interactions.

Why Puffer UniFi?

The proliferation of Layer 2 solutions has fragmented the Ethereum network, leading to a disjointed and inefficient blockchain ecosystem. Puffer UniFi tackles this fragmentation by offering a unified liquidity layer and enabling synchronous composability across different blockchain applications. This not only simplifies the user experience but also ensures a more equitable and transparent transaction process-free from the pitfalls of centralized sequencing.

UniFi also streamlines the deployment and operation of decentralized applications through a robust based app-chain ecosystem. By enabling individual dApps to launch their own based app-chains, UniFi creates an environment where these applications can operate with greater autonomy while still benefiting from Ethereum’s overarching security and decentralized architecture. This model promotes scalability and efficiency, allowing dApps to tailor their blockchain interactions specifically to their needs without sacrificing interoperability or security.

Vision for the Future

Puffer UniFi is not just a technological upgrade-it is a strategic enhancement designed to ensure the long-term viability and leadership of Ethereum in the blockchain space. By re-aligning incentives and reducing dependencies on intermediary structures, Puffer UniFi is set to reinforce Ethereum’s position as a robust and scalable platform.

“At Puffer, we’re addressing Ethereum’s fragmentation by fundamentally changing how transactions are sequenced for the better of Ethereum,” said Amir, Core Contributor to Puffer. “UniFi isn’t just another rollup; it’s the catalyst for a unified Ethereum ecosystem, one that delivers the UX to onboard the next billion users.”

Puffer invites all developers and blockchain enthusiasts to join in this transformative journey and contribute to a more integrated and sustainable blockchain environment.

Explore Puffer’s Vision

For a deeper understanding of Puffer UniFi and its potential impact on the Ethereum blockchain, interested parties are encouraged to read the detailed litepaper.

Read the full litepaper here: https://drive.google.com/file/d/1cgptQYM3B3r7M4Z74xb4AXfD7gdbRGLW/view

For further information, media contacts, or interviews, please contact us at the following channels:

Twitter: https://twitter.com/puffer_finance

Discord: https://discord.com/invite/pufferfi

Telegram: https://t.me/puffer_fi

Media Contact

[email protected]

Luke loo

SOURCE: UniFi

BXT-25 is expected to oxygenate the brain and be monitored by Bioxytran’s FDA approved medical device to trace all oxygen molecules

BOSTON, MASSACHUSETTS, July 8, 2024 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer’s disease, announced that Bioxtran’s Science Advisor Prof. Avraham Mayevsky’s book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions was published by a publishing house, Springer.  It is available by eBook or Hardcover.  The book is directly tied to the Hypoxia platform technology which uses the MDX Viewer as an analytical method, which is an FDA approved device to measure tissue oxygenation.  The device measures the consumption of oxygen molecules in tissues on a cellular level.  The output of the MDX Viewer is the Brain Metabolic Score BMS, which is a vital part of the approval process for Bioxytran’s acellular oxygen carrier (AOC) molecule called BXT-25.  Bioxytran plans on using the BXT-25 in its clinical trials for ischemic stroke and Alzheimer’s disease patients as a way to replace hyperbaric oxygen treatment (HBOT). 

https://link.springer.com/book/10.1007/978-3-031-49681-3

The book is a comprehensive overview of the effects of hyperbaric oxygen on brain functions including mitochondrial activity.  The MDX viewer is an FDA approved medical device that measures tissue metabolic score and its results are cited many times throughout the book.  The results from the MDX viewer provided a solid foundation upon which he was able to further elucidate the relationship between oxygenation and cerebral function with respect to hyperbaric oxygenation treatment.  The book also discusses the effects of hyperbaric oxygen treatment on brain biochemical and physiological responses that can influence mitochondrial activity, which is essential for energy production.  The evidence suggests that hyperbaric oxygen improves cerebral blood flow and tissue oxygenation which ultimately results in a positive impact on brain functioning and performance.   

“BXT-25 is expected to oxygenate the brain and other human organs and tissues,” said Avraham Mayevsky, Member of Bioxytran’s Medical Advisory Board.  “One of the biggest challenges in in clinical trials is determining the efficacy of a drug. One of the most widely held beliefs in medicine is that increased mitochondrial activity at the cellular level means cells are working more efficiently and that ultimately leads to a demonstration of efficacy of a drug.  The MDX viewer is an FDA approved device that monitors oxygenation in real time and is so sensitive, that it’s conceivable future applications could be used as an endpoint of efficacy.  Drugs capable of treating diseases will ultimately impact they body by increasing the BMS.  This means that if a patient baseline BMS is established and then an efficacious drug is introduced the BMS will rise.  Conversely if a drug is tested on a person who experiences side effects, its likely the BMS will go down.  Since BXT-25 is essentially a miniaturized oxygen carrier we would expect to see favorable increases in BMS.  Coupling the MDX Viewer in clinical trials with drugs like BXT-25 could significantly shorten the clinical trial processes an demonstrate efficacy on a cellular level using an unbiased biomarker instead of surrogate biomarkers to demonstrate efficacy.  Ultimately, I see this will shorten the time for FDA approval as a universal oxygen carrier for tissue oxygenation.” 

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical stage biotechnology company developing a drug to treat stroke in an early stage and Alzheimer’s disease by delivering oxygen with a molecule that is 5000 times smaller than a red blood cell.    More information can be found at www.bioxytraninc.com

Investor Relations

Michael Sheikh

509-991-0245

[email protected]

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

Media Contact:

[email protected]

6175102539

www.bioxytrantinc.com 

Bioxytran

David Platt